Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric M. Dube Sells 50,691 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric M. Dube sold 50,691 shares of Travere Therapeutics stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $20.21, for a total value of $1,024,465.11. Following the sale, the chief executive officer now owns 430,548 shares in the company, valued at $8,701,375.08. This trade represents a 10.53 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Travere Therapeutics Stock Up 4.4 %

Shares of NASDAQ TVTX opened at $21.10 on Wednesday. The company’s fifty day moving average is $18.69 and its two-hundred day moving average is $15.47. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. Travere Therapeutics, Inc. has a one year low of $5.12 and a one year high of $21.56.

Institutional Investors Weigh In On Travere Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of TVTX. Creative Planning raised its holdings in Travere Therapeutics by 4.3% during the third quarter. Creative Planning now owns 23,938 shares of the company’s stock worth $335,000 after purchasing an additional 995 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Travere Therapeutics by 2.2% during the 4th quarter. Rhumbline Advisers now owns 121,248 shares of the company’s stock worth $2,112,000 after buying an additional 2,640 shares during the last quarter. R Squared Ltd acquired a new position in shares of Travere Therapeutics during the 4th quarter worth $53,000. CWM LLC boosted its position in shares of Travere Therapeutics by 158.5% in the 3rd quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after buying an additional 3,065 shares in the last quarter. Finally, Diversified Trust Co grew its stake in Travere Therapeutics by 27.5% in the 4th quarter. Diversified Trust Co now owns 14,701 shares of the company’s stock valued at $256,000 after acquiring an additional 3,169 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on TVTX. Piper Sandler raised their price target on Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a research note on Thursday, November 14th. Scotiabank lifted their price objective on shares of Travere Therapeutics from $23.00 to $27.00 and gave the company a “sector outperform” rating in a research note on Friday, November 1st. Bank of America increased their target price on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Cantor Fitzgerald assumed coverage on Travere Therapeutics in a research report on Friday, January 10th. They issued an “overweight” rating on the stock. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Travere Therapeutics in a research report on Tuesday, October 8th. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $24.00.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.